NFL Biosciences SA (ALNFL.PA)
| Previous close | 3.9600 |
| Open | 3.9000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 3.8200 - 3.9600 |
| 52-week range | 3.0000 - 5.0000 |
| Volume | 1,399 |
| Avg. volume | 12,228 |
| Market cap | 20.415M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.90 |
- Globe Newswire
NFL Biosciences: Availability of the Half Year Financial Report as of June 30, 2021
NFL Biosciences: Availability of the Half Year Financial Report as of June 30, 2021 NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL a biopharmaceutical company developing botanical drugs for the treatment of addictions, announced today, Monday, October 4, 2021, that it has made available to the public and filed with the Autorité des Marchés Financiers (AMF) its Half Year Financial Report for the period ended June 30, 2021. The Half-Year Financial Report can be consulted on the comp
- Globe Newswire
NFL BIOSCIENCES: 2021 half-year financial and business report
NFL Biosciences: 2021 half-year financial and business report Admission on Euronext Growth Paris: €5m raised from institutional, historical, and individual investors (July 2021) CESTO II Phase II/III clinical trial approved in Australia (May 2021) and France (September 2021) Clinical team strengthened NFL Bioscience’s patent issued in the US (September 2021) “Innovative company” qualification by BPIfrance recognized NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceuti
- Globe Newswire
NFL BIOSCIENCES: approval for its patent to be granted in the United States
NFL BIOSCIENCES: approval for its patent to be granted in the United States NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that the United States Patent and Trademark Office (USPTO) issued, on September 21 with number US 11123395, the patent for NFL-101, a nicotine-free botanical drug candidate comprising natural proteins extracted from tobacco leaves, focused primarily on smoki
